- Home
- PULM vs EQ Comparison
PULM vs EQ Comparison
Compare PULM & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- EQ
- Stock Information
- Founded
- PULM 2003
- EQ 2017
- Country
- PULM United States
- EQ United States
- Employees
- PULM N/A
- EQ N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- PULM Health Care
- EQ Health Care
- Exchange
- PULM Nasdaq
- EQ Nasdaq
- Market Cap
- PULM 21.0M
- EQ 24.8M
- IPO Year
- PULM N/A
- EQ 2018
- Fundamental
- Price
- PULM $7.10
- EQ $0.66
- Analyst Decision
- PULM
- EQ Buy
- Analyst Count
- PULM 0
- EQ 2
- Target Price
- PULM N/A
- EQ $5.00
- AVG Volume (30 Days)
- PULM 37.6K
- EQ 166.1K
- Earning Date
- PULM 03-27-2025
- EQ 03-24-2025
- Dividend Yield
- PULM N/A
- EQ N/A
- EPS Growth
- PULM N/A
- EQ N/A
- EPS
- PULM N/A
- EQ N/A
- Revenue
- PULM $10,005,000.00
- EQ $45,914,000.00
- Revenue This Year
- PULM N/A
- EQ $4.77
- Revenue Next Year
- PULM $1.00
- EQ N/A
- P/E Ratio
- PULM N/A
- EQ N/A
- Revenue Growth
- PULM 47.05
- EQ 7.70
- 52 Week Low
- PULM $1.55
- EQ $0.49
- 52 Week High
- PULM $8.44
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- PULM 62.30
- EQ 45.39
- Support Level
- PULM $6.84
- EQ $0.49
- Resistance Level
- PULM $8.14
- EQ $0.70
- Average True Range (ATR)
- PULM 0.39
- EQ 0.07
- MACD
- PULM 0.11
- EQ -0.00
- Stochastic Oscillator
- PULM 71.43
- EQ 60.50
About PULM Pulmatrix Inc.
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.